EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial

Rachel M Holden iD, Sarah L Booth, Deborah Zimmerman iD, Louise Moist, Patrick A Norman, Andrew G Day, Alex Menard, Xueyan Fu, M Kyla Shea, Corinne S Babiolakis, Robert Nolan, Mandy E Turner und 4 weitere

Nephrology Dialysis Transplantation · 28.02.2023 · 38 (3) · 746-756

DOI: 10.1093/ndt/gfac191 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 31.05.2022. Verfasst von Rachel M Holden und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Coronary Artery Disease, Vascular Calcification. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Canadian Institutes of Health Research, USDA Agricultural Research Service.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitamin K activates matrix Gla protein (MGP), a key inhibitor of vascular calcification. There is a high prevalence of sub-clinical vitamin K deficiency in patients with end-stage kidney disease.

Methods

A parallel randomized placebo-controlled pilot trial was designed to determine whether 10 mg of phylloquinone thrice weekly versus placebo modifies coronary artery calcification progression over 12 months in patients requiring hemodialysis with a coronary artery calcium score (CAC) ≥30 Agatston Units (ClinicalTrials.gov identifier NCT01528800). The primary outcome was feasibility (recruitment rate, compliance with study medication, study completion and adherence overall to study protocol). CAC score was used to assess calcification at baseline and 12 months. Secondary objectives were to explore the impact of phylloquinone on vitamin K-related biomarkers (phylloquinone, dephospho-uncarboxylated MGP and the Gla-osteocalcin to Glu-osteocalcin ratio) and events of clinical interest.

Results

A total of 86 patients with a CAC score ≥30 Agatston Units were randomized to either 10 mg of phylloquinone or a matching placebo three times per week. In all, 69 participants (80%) completed the trial. Recruitment rate (4.4 participants/month) and medication compliance (96%) met pre-defined feasibility criteria of ≥4.17 and ≥90%, respectively. Patients randomized to phylloquinone for 12 months had significantly reduced levels of dephospho-uncarboxylated MGP (86% reduction) and increased levels of phylloquinone and Gla-osteocalcin to Glu-osteocalcin ratio compared with placebo. There was no difference in the absolute or relative progression of coronary artery calcification between groups.

Conclusion

We demonstrated that phylloquinone treatment improves vitamin K status and that a fully powered randomized trial may be feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseVascular CalcificationHumansVitamin KVitamin K 1OsteocalcinPilot ProjectsCalcium-Binding ProteinsExtracellular Matrix ProteinsRenal DialysisVitamin K 2

Stichwörter der Autor:innen

chronic kidney diseasecoronary artery calcificationphylloquinonerandomized pilotvitamin K

Substanzen

Vitamin KVitamin K 1OsteocalcinCalcium-Binding ProteinsExtracellular Matrix ProteinsVitamin K 2

Autor:innen und Institutionen

  • Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Department of Biomedical and Molecular Science, Queen's University, Kingston, Ontario, Canada.
  • Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
  • Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Kingston General Health Research Institute, Kingston Health Sciences Center, Kingston, Ontario, Canada.

ORCID-Profile: Rachel M Holden, Deborah Zimmerman

Förderung

  • Canadian Institutes of Health Research
  • USDA Agricultural Research Service

Zitieren

APA

Holden, R. M., Booth, S. L., Zimmerman, D., Moist, L., Norman, P. A., Day, A. G., Menard, A., Fu, X., Shea, M. K., Babiolakis, C. S., Nolan, R., Turner, M. E., Ward, E., Kaufmann, M., Adams, M. A., & Heyland, D. K. (2023). Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial. Nephrology Dialysis Transplantation, 38(3), 746-756. https://doi.org/10.1093/ndt/gfac191

Vancouver

Holden RM, Booth SL, Zimmerman D, Moist L, Norman PA, Day AG, et al. Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial. Nephrology Dialysis Transplantation. 2023;38(3):746-756. doi:10.1093/ndt/gfac191

BibTeX
@article{Holden2023,
  author = {Holden, Rachel M and Booth, Sarah L and Zimmerman, Deborah and Moist, Louise and Norman, Patrick A and Day, Andrew G and Menard, Alex and Fu, Xueyan and Shea, M Kyla and Babiolakis, Corinne S and Nolan, Robert and Turner, Mandy E and Ward, Emilie and Kaufmann, Martin and Adams, Michael A and Heyland, Daren K},
  title = {Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {3},
  pages = {746--756},
  doi = {10.1093/ndt/gfac191}
}
Kostenlos starten →